Fig. 2
From: Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia
In vivo assessment of an anti-sortilin antibody in a mouse model of GRN haploinsufficiency. A Cell lysate sortilin levels and B plasma PGRN levels from WT and Grn+/− mice that received weekly i.p. injections of S15JG or isotype control for 4.5 weeks. C PGRN levels measured from ISF 33–48 h post injection demonstrated a significant main effect of antibody treatment (P = 0.0089) by Mann–Whitney U tests. (A-C) N = 4–6 per group. All data represent the mean ± SEM. P values are by planned post hoc Tukey’s tests and are adjusted for multiple comparisons. D Schematic of social dominance test. E–H Ratio of the number of matches won by each animal in a given matchup. Male and female pairs were tested at 19–21 months of age (n = 9–12 per group). P values are by Mann–Whitney U tests. All data represent the mean ± SEM. Anti-sort, anti-sortilin antibody S15JG; Ctl, control; ISF, interstitial fluid; PGRN, progranulin